Biofrontera Inc. (BFRI)

↓ Download CSV

CIK 0001858685 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Biofrontera Inc. reported revenue of $41.70M, up 11.7% from the prior year. The company ran a net loss, with a net margin of -25.3%. It held $28.56M in total assets against $18.08M in total liabilities.

Key ratios (FY2025)

-27.2%
Operating margin
-25.3%
Net margin
-100.5%
Return on equity
+11.7%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019
Revenue$41.70M$37.32M$34.07M$28.67M$24.04M$18.85M
Operating Income-$11.35M-$17.21M-$22.68M-$18.58M-$25.20M-$9.61M
Net Income-$10.54M-$17.76M-$20.13M-$640.0K-$37.71M-$10.99M
EPS (Diluted)$-1.04$-3.22$-13.02$-0.61$-85.63
Total Assets$28.56M$22.10M$27.93M$50.88M$53.22M$24.14M
Total Liabilities$18.08M$17.67M$23.14M$27.01M$41.88M$18.31M
Shareholders' Equity$10.48M$4.43M$4.79M$23.88M$11.34M$5.83M-$30.18M
Cash & Equivalents$6.39M$5.91M$1.34M$17.21M$24.55M$8.08M
Operating Cash Flow-$13.36M-$10.27M-$24.89M-$16.20M-$26.71M-$12.37M
Capital Expenditures$2.0K$10.0K$5.0K$38.0K
Shares Outstanding11.65M8.87M1.52M1.33M855.2K8.00M